SEC Comment Letter 0000000000-23-009534 to Sunshine Biopharma Inc. (SBFM)

Sunshine Biopharma Inc.
Date: Aug. 29, 2023 · CIK: 0001402328 · Accession: 0000000000-23-009534

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-41282

Date

August 29, 2023

Author

Camile Sebaaly

Form

UPLOAD

Company

Sunshine Biopharma Inc.

Letter

United States securities and exchange commission logo August 29, 2023 Camile Sebaaly Chief Financial Officer Sunshine Biopharma, Inc. 6500 Trans-Canada Highway Pointe-Claire, Quebec Canada H9R-0A5 Re:Sunshine Biopharma, Inc Form 10-K for the Fiscal Year Ended December 31, 2022 Filed April 4, 2023 File No. 001-41282 Dear Camile Sebaaly: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
August 29, 2023
Camile Sebaaly
Chief Financial Officer
Sunshine Biopharma, Inc.
6500 Trans-Canada Highway
Pointe-Claire, Quebec
Canada H9R-0A5
Re:Sunshine Biopharma, Inc
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed April 4, 2023
File No. 001-41282
Dear Camile Sebaaly:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io